Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 21, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first...
July 20, 2026 16:30 ET | Source: Calidi Biotherapeutics, Inc

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic...
June 23, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...
June 16, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...
September 29, 2025 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of...
July 10, 2025 08:30 ET | Source: Calidi Biotherapeutics Inc.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...
July 08, 2025 08:30 ET | Source: Calidi Biotherapeutics Inc.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...
September 13, 2023 05:50 ET | Source: First Light Acquisition Group

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics...
September 11, 2023 16:05 ET | Source: First Light Acquisition Group

First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments

Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total...
August 24, 2023 12:06 ET | Source: First Light Acquisition Group

FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that it reconvened and then further adjourned, without conducting any other...